Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
Giuseppe Di Lorenzo(Saint Camillus International University of Health and Medical Sciences), Sabino De Placido, Antonio Giordano(University of Siena), Nicola Longo(University of Naples Federico II), Vincenzo Mirone(University of Naples Federico II), Riccardo Autorino(Rush University Medical Center), Ciro Imbimbo(University of Naples Federico II), Mario Giuliano(Regione Campania), Sophie D. Fosså(Oslo University Hospital), William D. Figg(National Institutes of Health), Roberto Labianca(Ospedale Papa Giovanni XXIII), Sisto Perdonà(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 128
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Curcumin and Cancer
|Nutrients|2019|977
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
|The Lancet|2008|873
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
|JNCI Journal of the National Cancer Institute|2005|830